IIVS, Non Animal Testing, Alternative Test Methods, In Vitro Toxicology | Direct Peptide Reactivity Activation Assay (DPRA, OECD 442C)
606
page-template-default,page,page-id-606,page-child,parent-pageid-540,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Direct Peptide Reactivity Activation Assay (DPRA, OECD 442C)

The DPRA  (OECD 442C) is an in chemico assay that  models the first key event in the skin sensitization Adverse Outcome Pathway (AOP) – skin, protein reactivity.

  • Compounds implicated in causing Allergic Contact Dermatitis (ACD) are generally electrophilic in nature. This assay identifies dermal sensitizers based on their reactivity with synthetic peptides containing the nucleophilic amino acid residues lysine and cysteine. Using LC/UV, conjugation of the test material with the peptides can be analyzed.
  • Trained by the developers of this assay (Procter & Gamble), IIVS offers this service in compliance with the OECD 442C test guideline as well as Good Laboratory Practices for regulatory submissions.
  • IIVS performs DPRA in combination with other in vitro methods to assess the skin sensitization potential of chemicals – such as KeratinoSens and hCLAT – as part of an Integrated Testing Strategy.

Assay Features

• Compatible with a range of solvent systems
• Rapid-turnaround
• Internationally Recognized (OECD) test guideline
• Inexpensive relative to animal testing

Prepared samples to be loaded into the Separation Module.

Please contact IIVS for more information on the DPRA assay and how it may be suitable for your organization’s testing needs.